Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBT Margin: 2012-2025

Historic EBT Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to -803.05%.

  • Agios Pharmaceuticals' EBT Margin fell 1197033.00% to -803.05% in Q3 2025 from the same period last year, while for Sep 2025 it was -919.64%, marking a year-over-year decrease of 312285.00%. This contributed to the annual value of 1,967.15% for FY2024, which is 327978.00% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' EBT Margin stood at -803.05%, which was up 11.13% from -903.60% recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' EBT Margin peaked at 11,167.28% during Q3 2024, and registered a low of -12,073.44% during Q1 2022.
  • In the last 3 years, Agios Pharmaceuticals' EBT Margin had a median value of -1,037.61% in 2025 and averaged -3.48%.
  • Per our database at Business Quant, Agios Pharmaceuticals' EBT Margin surged by 1,240,156bps in 2024 and then crashed by 1,197,033bps in 2025.
  • Agios Pharmaceuticals' EBT Margin (Quarterly) stood at -2,150.44% in 2022, then soared by 79,974bps to -1,350.70% in 2023, then skyrocketed by 36,841bps to -982.28% in 2024, then tumbled by 1,197,033bps to -803.05% in 2025.
  • Its EBT Margin stands at -803.05% for Q3 2025, versus -903.60% for Q2 2025 and -1,037.61% for Q1 2025.